CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
about
Source-Related Effects of Wastewater on Transcription Factor (AhR, CAR and PXR)-Mediated Induction of Gene Expression in Cultured Rat Hepatocytes and Their Association with the Prevalence of Antimicrobial-Resistant Escherichia coliPredicting drug-target interaction networks based on functional groups and biological featuresAuto-Induction Effect of Chloroxoquinoline on the Cytochrome P450 Enzymes of Rats Associated with CYP 3A and 1AScreening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax GinsengComputational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and softwareDrug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.Evaluation of metabolism-mediated herb-drug interactions.CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR.Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction toolEstimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.Organotypic liver culture models: meeting current challenges in toxicity testing.Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method.Interplay between vitamin D and the drug metabolizing enzyme CYP3A4Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.Transporter-mediated drug interactions: clinical implications and in vitro assessment.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Cytochrome P450 reaction-phenotyping: an industrial perspective.Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.Age-Specific Regulation of Drug-Processing Genes in Mouse Liver by Ligands of Xenobiotic-Sensing Transcription Factors.Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes.Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in miceInteractions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications.Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation.Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression.Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.The role of diet on the clinical pharmacology of oral antineoplastic agents.Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications.Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.The effects of Andrographis paniculata (Burm.f.) Nees extract and diterpenoids on the CYP450 isoforms' activities, a review of possible herb-drug interaction risks.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Human pregnane X receptor is activated by dibenzazepine carbamate-based inhibitors of constitutive androstane receptor.
P2860
Q28389019-7C94AC19-C01B-4CA1-A64B-E910AD1E0B4CQ28473160-68387734-5F56-48BA-939E-D9F846EDB641Q28548385-3D42E892-502B-47BE-96D0-7E83046BE487Q28553125-D7C254F8-7312-4560-B8A6-D813FB906794Q28659783-9470CE24-4438-4F79-ADC4-F11B79AA3396Q33509452-D08FBACB-0AF7-471F-81CE-EF6923B43E9FQ34238039-877A5C7E-081F-4D49-8075-50D0FCBFD009Q34458070-B4492FB8-47E7-4270-A9AB-3AAFDECE07B1Q34522043-A8305BC3-0C5A-42B1-88B2-A4BFE126D914Q34542725-D28075A6-DC34-4616-AA6D-19058B43EF51Q35113280-4B4EFF2B-92C1-4244-939B-672CAC8A4813Q35718630-DDBD41A3-6AAE-42B3-AAC0-A262687C099CQ36178225-2D7A1144-C3C9-40F1-9DA1-CC69889CE8ECQ36205082-D16334D7-7F22-4F14-A719-48BA58A753F9Q36545257-6C370520-7DAB-4A26-906F-A0776393511DQ36578060-F7BFB74D-9CD0-4471-9069-52FADE3B7792Q36725222-E40565C1-B118-44B1-93A0-9C2B164E1818Q36960535-60324AE9-0CDF-4420-891D-09736AE1AF21Q36960539-52E9DF99-FBD5-4ADA-AD06-BD740738954CQ36985079-ECDB0EC5-5F81-481C-967F-9742E2FF4C9EQ36985086-796D0A5A-19C0-4617-B6AF-9EBE5CD38E5CQ37062595-067795B9-E5BF-4C6A-86CF-535375984933Q37118793-CF7A4593-9776-4C51-B0C0-2EAD03246562Q37352712-E4DEA312-7A90-442A-AF62-04F0C440F594Q37497393-A74DAD04-A066-48A3-9210-B4F43A481A24Q37557621-40B70CBE-1A43-435F-A8C6-1801F2204CEEQ37693956-881EEE14-40C1-4D09-AB1B-00B5862F10B7Q37728687-743E2C86-B7E3-4024-A312-6B2D67755177Q37771144-6701F0C0-11A1-4EE9-824F-E3B09F55436DQ37907103-FB501C91-CF79-446B-95DE-A4F1B8E1B1D5Q38011807-9DF4385D-17FC-4231-8998-B34F8C608C27Q38028549-7F2BEA3C-21D1-4DA5-88D5-B32D0EB360F5Q38057372-55DCEC92-2289-41AB-9579-24E3EF88B15AQ38089823-0CEDF80E-FB43-4FAC-BC29-9ED83ED83D3DQ38128592-01390D72-6A8E-4296-AB8C-2845257E7BF1Q38170449-12F4F44A-6C9D-4E63-A96D-D92A895D1AACQ38180822-DF871B0F-A7BB-4E4E-BD8C-7EBA0D1E48F7Q38243181-699E06FD-6714-4FD8-A821-F204FC47617BQ38346846-96123311-1F39-4918-90A9-07A09EE2A586Q38910106-A1690E3E-6306-4E86-B383-F4BF6BB3A2CC
P2860
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@ast
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@en
type
label
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@ast
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@en
prefLabel
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@ast
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@en
P2860
P1476
CYP induction-mediated drug interactions: in vitro assessment and clinical implications.
@en
P2093
Jiunn H Lin
P2860
P304
P356
10.1007/S11095-006-0277-7
P577
2006-05-26T00:00:00Z